Midjourney Unveils Water-Based Full-Body Ultrasound Scanner
Midjourney publicly unveiled Midjourney Medical and a prototype full-body ultrasound scanner on June 18, 2026, built on a five-year, up-to-$74 million licensing deal with NYSE-listed Butterfly Network first disclosed in a Nov. 2025 SEC filing. The water-immersion scanner uses roughly half a million ultrasonic sensors and about 2 petaflops of compute to produce a 3D body scan in about 60 seconds, which Midjourney says will approach MRI-level detail at far higher speed; Butterfly's Ultrasound-on-Chip technology powers the underlying hardware. For practitioners, the story is less about AI models and more about hardware-data co-design: massive per-scan data volumes, distributed real-time reconstruction, and a phased regulatory path, since Midjourney is launching with non-diagnostic body-composition maps first and plans incremental FDA submissions. Butterfly Network shares rose more than 50% on the news, according to MobiHealthNews, while independent imaging experts cited by The Verge say clinical parity with MRI remains unproven.
Midjourney's jump from an image generator to a licensed medical-hardware platform is a useful case study in how a compute-rich AI company scales beyond model training into physical sensing and real-time signal reconstruction. The harder engineering problem here is not a language or vision model, it is a data-engineering one: turning roughly a million ultrasonic echoes per second into a body-scale 3D reconstruction fast enough to work as a wellness product rather than a research demo, all while staying inside a deliberately narrow, non-diagnostic regulatory lane.
What happened
Midjourney publicly announced Midjourney Medical and The Midjourney Scanner on June 18, 2026, in its own blog post, describing a prototype that submerges a user in a shallow pool of water and passes them through a ring of ultrasonic sensors to build a 3D image of the body in about 60 seconds. The same day, Butterfly Network (NYSE: BFLY), a semiconductor-ultrasound company, confirmed it supplies the Ultrasound-on-Chip technology inside the scanner, with CEO Joseph DeVivo calling it "the next generation of AI on device." The Verge separately reported that company engineer Marcin Plaza produced a behind-the-scenes tour video of the hardware, and that independent imaging experts told reporters Midjourney has so far shown limited evidence the system overcomes known ultrasound limits or matches MRI-level diagnostic detail.
Timeline
Butterfly Network disclosed in an SEC Form 8-K that it had signed a five-year, up-to-$74 million co-development and licensing agreement, later revealed to be with Midjourney.
Midjourney publicly unveiled Midjourney Medical and the Midjourney Scanner, and Butterfly Network confirmed its ultrasound-on-chip technology powers the device.
Technical context
Midjourney's own materials describe a ring of about half a million small ultrasonic elements, each acting as both a speaker and a microphone, generating on the order of terabytes of raw data per second of scan; an earlier technical write-up from Latent.space cited a lower total of 358,000 elements, so precise sensor counts vary somewhat by source. Reconstruction reportedly runs on a large server cluster, with Butterfly Network's CEO citing "over two petaflops" of processing power, and Midjourney says the resulting body-scale map approaches MRI resolution at close to a hundred times the speed. The company has said the reconstruction pipeline is not yet using AI, describing it instead as "really cool hardware and software," according to HTWorld.
Financial context
Per MobiHealthNews' reporting on Butterfly's SEC filing, the licensing agreement runs five years and includes a one-time $15 million fee, a $10 million annual license fee paid quarterly, up to $9 million in milestone payments, and additional per-chip and commercialization payments, for a disclosed maximum of $74 million. Butterfly Network shares reportedly rose more than 50%, from $5.84 to $8.90, following the announcement, per MobiHealthNews. Midjourney itself remains self-funded, saying it has never taken venture capital or institutional investment despite reported hundreds of millions of dollars in annual revenue.
For practitioners
The interesting systems problem is less modeling and more pipeline engineering: ingesting and compressing very high-throughput sensor data, distributing wave-to-image reconstruction across a large compute cluster, and doing all of it inside a regulatory lane that avoids diagnostic claims for now. Teams evaluating similar sensor-heavy, real-time reconstruction products should note Midjourney's phased approach: shipping non-diagnostic "body composition maps" first and submitting incremental test results to the FDA as it seeks broader clearance.
What to watch
Midjourney's own roadmap targets a first "research spa" within about 12 months, a San Francisco Midjourney Spa location by the end of 2027, a redesigned third-generation scanner with custom silicon in 2028, and a goal of roughly 50,000 scanners and a billion scans a month worldwide by 2031. Given the skepticism from independent imaging experts cited by The Verge, the more immediate signals to track are any peer-reviewed validation, FDA submission progress, and results from Midjourney's planned clinical trials.
Editorial analysis
Framing a high-throughput imaging system as a wellness and spa product, rather than a diagnostic device, is a common industry pattern for companies trying to reach consumers before clearing the higher regulatory bar that diagnostic claims require; it lets a company gather real-world usage and data while deferring harder validation work, a strategy also used elsewhere in consumer health tech.
Key Points
- 1Midjourney unveiled Midjourney Medical on June 18, 2026, a water-immersion ultrasound scanner built on a licensed Butterfly Network chip partnership disclosed months earlier.
- 2The deal, filed with the SEC in November 2025, is worth up to $74 million and sent Butterfly Network's stock up over 50%.
- 3Midjourney plans a non-diagnostic wellness rollout first, submitting incremental FDA test results toward eventual diagnostic-grade clearance and scale.
Scoring Rationale
Raises from a vague hardware-reveal framing to a confirmed, financially material story: a five-year, up-to-$74M SEC-disclosed licensing deal with NYSE-listed Butterfly Network, an official product launch, and a double-digit-percent stock reaction. Capped below 'major' because the device is unproven clinically, non-diagnostic at launch, and adjacent to core AI/ML rather than a model or research breakthrough.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
